info@seagull-health.com
SeagullHealth
search
Cobimetinib(Cotellic)
Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.
Cotellic(Cobimetinib) Instructions:Uses,Dosage, Side Effects
Cotellic (cobimetinib) is an oral kinase inhibitor primarily utilized in oncology. It works by inhibiting MEK1 and MEK2, key enzymes in the MAPK/ERK signaling pathway, which plays a crucial role in cell division and survival. By blocking this pathway, Cotellic helps slow down the growth of cancer cells.
This drug is approved for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib. Additionally, it is approved for the treatment of adult patients with histiocytic neoplasms as a monotherapy. It is essential for clinicians to confirm the presence of the BRAF V600E or V600K mutation before initiating Cotellic in melanoma patients.
1.Unresectable or Metastatic Melanoma:
For adults with BRAF V600E/K mutation-positive disease, in combination with vemurafenib.
2.Histiocytic Neoplasms:
As monotherapy for adults with histiocytic neoplasms (e.g., Erdheim-Chester disease, Langerhans cell histiocytosis).
1.Melanoma:
60 mg once daily for 21 days followed by 7 days off (28-day cycle).
Confirm BRAF V600 mutation before initiation.
2.Histiocytic Neoplasms:
60 mg once daily for 21 days followed by 7 days off (28-day cycle).
- Core products
- Antitumor drugs
- General drug
- Antiviral drugs
- Biological agents
- mailbox：info@lucius.la
